S*BIO Signs Dev Deal with Tragara Pharma
S*BIO Pte Ltd. of Singapore has granted San Diego-based Tragara Pharmaceuticals a global exclusive license to develop and commercialize multi-kinase inhibitor SB1317. Under terms of the agreement, S*BIO is eligible to receive up to $112.5 million in payments, including both up-front fees and earn-outs. S*BIO has raised over $26 million from firms like Aravis Capital, Bio*One Capital, Lacuna Apo BioTech Fund and Zurcher Kantonalbank. Tragara Pharma has raised $40 million from Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Biosceince Partners and Mitsubishi International Corp.
21 January 2009•3 mins read
